Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer

This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.

Inclusion Criteria: * \* Age 35-70 years * Capable of providing informed consent * Prognosis of \> 5 years if affected by another cancer * Patients need one to meet at least one of the following high genetic risk categories: * Known PCa-related mutations: BRCA 1 and 2, Lynch syndrome, or p53 * Carrier of mutation in a suspected PCa-related gene: e.g., ATM, PALB2, CHEK2, RAD51D, ATR, NBN, GEN1, RAD51C, MRE11A, BRIP1, FAM175A, HOXB13 * Obligate carriers of the above mutations (e.g. their sisters/daughters have known mutations) * Men with any family history of above mutation * Family history of breast, prostate, or ovarian cancer in at least 2 individuals, or in 1 individual diagnosed before age 50 Exclusion Criteria: * \* Anuria * Prior diagnosis or treatment for PCa * Failure to provide informed consent * Life expectancy \< 5 years